• 제목/요약/키워드: therapeutic agents

검색결과 790건 처리시간 0.027초

AcrAB-TolC, a major efflux pump in Gram negative bacteria: toward understanding its operation mechanism

  • Soojin Jang
    • BMB Reports
    • /
    • 제56권6호
    • /
    • pp.326-334
    • /
    • 2023
  • Antibiotic resistance (AR) is a silent pandemic that kills millions worldwide. Although the development of new therapeutic agents against antibiotic resistance is in urgent demand, this has presented a great challenge, especially for Gram-negative bacteria that have inherent drug-resistance mediated by impermeable outer membranes and multidrug efflux pumps that actively extrude various drugs from the bacteria. For the last two decades, multidrug efflux pumps, including AcrAB-TolC, the most clinically important efflux pump in Gram-negative bacteria, have drawn great attention as strategic targets for re-sensitizing bacteria to the existing antibiotics. This article aims to provide a concise overview of the AcrAB-TolC operational mechanism, reviewing its architecture and substrate specificity, as well as the recent development of AcrAB-TolC inhibitors.

선천성 대사 이상 질환에서의 골격계 증상 발현 (Skeletal Manifestations of Inborn Errors of Metabolism: A Comprehensive Retrospect)

  • 조성윤
    • 대한유전성대사질환학회지
    • /
    • 제23권1호
    • /
    • pp.1-11
    • /
    • 2023
  • Inborn errors of metabolism encompass a wide variety of disorders, frequently affecting bone. This review presents a comprehensive retrospect on the primary involvement of bone in inborn errors of metabolism. Primary involvement of bone in inborn errors of metabolism includes entities that primarily affect the bone marrow, mineral component or cartilage. These include lysosomal storage disorders, hypophosphatasia, and hereditary hypophosphatemic rickets. In this review, we discuss the primary involvement of bone in inborn errors of metabolism (hypophosphatasia, X-linked hypophosphatemic rickets, Gaucher disease, and mucopolysaccharidoses) along with the therapeutic agents used in clinical settings, diagnostic strategies, and general management. With the development of disease-specific targeted therapies and supportive care, more number of patients with these disorders live longer and survive into adulthood. Moreover, skeletal symptoms have become a more prominent feature of these disorders. This makes the awareness of these skeletal symptoms more important.

  • PDF

중증 폐혈전색전증 환자에서 Urokinase와 Alteplase의 효과 및 출혈 합병증 비교 (The Therapeutic Efficacy and the Bleeding Complications of Urokinase and Alteplase in Patients with Massive Pulmonary Thromboembolism)

  • 유정완;김원영;최창민;홍상범;오연목;심태선;임채만;이상도;김우성;김동순;김원동;고윤석
    • Tuberculosis and Respiratory Diseases
    • /
    • 제66권1호
    • /
    • pp.6-12
    • /
    • 2009
  • 연구배경: 폐혈전색전증 환자에서 혈전용해제의 효과는 차이가 없는 것으로 보고되어 있으나 출혈 등의 부작용에 대해서는 잘 알려져 있지 않다. 본 연구는 한 병원에서 중증 폐혈전색전증환자들에 사용한 alteplase와 urokinase의 치료효과 및 출혈 유발 정도를 비교하였다. 방법: 2000년 1월부터 2008년 7월까지 대상 환자 40명을 urokinase군(16명)과 alteplase군(24명)으로 나누어 의무기록을 후향적으로 분석하였다. 결과: 혈전용해제 사용한 이유는 혈역학적 불안정 23명, 중증 우심실부전 7명 그리고 헤파린 사용에도 불구하고 진행하는 저산소증 10명이었다. 두 군간 나이, APACHE II, SOFA score, 혈전용해제에서 유의한 차이는 없었다. 혈전용해제를 사용 후 승압제의 사용기간에서 aletplase군이 urokinase군보다 더 짧았으나, 인공호흡기 사용 기간과 중환자실 입원기간에서는 양 군간 유의한 차이가 없었다. 입원기간 동안 사망한 환자수는 13명(30%)으로 urokinase와 alteplase군 5명, 8명으로 유의한 차이는 없었고, 폐혈전색전증과 연관된 사망한 환자수에서도 urokinase와 alteplase군에서 1명, 4명으로 유의한 차이는 없었다. 혈전용해제 사용 후 수술적 치료가 필요한 환자 수도 urokinase군 2명, alteplase군 1명으로 차이가 없었다. 혈전용해제 사용 후 발생한 출혈은 14명(35%)에서 관찰되었고 urokinase군 3명(7.5%), alteplase군 11명(27.5%)으로 urokinase군에서 적은 경향을 보였다. 중증 출혈은 2명으로 모두 alteplase군에서 발생하였으며 1명은 뇌출혈로 사망하였다. 결론: 중증 폐색전혈전증환자에서 urokinase 사용은 alteplase에 비하여 치료효과는 차이가 없으면서 출혈의 위험은 낮을 것으로 사료된다.

Effect of Dietary Chlorella Complex on Anticancer Activity in Mice

  • Jung Jae-Hak;Jin Kyong-Suk;Kim Yong-Ho;Lee Yong-Woo
    • 대한의생명과학회지
    • /
    • 제11권2호
    • /
    • pp.185-192
    • /
    • 2005
  • Dietary chlarella has known as one of the best candidates for development of multifunctional probiotic foods owing to an excellent nutritional value such as high amount of proteins and various, valuable fatty acids. So many efforts were devoted to studying the chlorella as therapeutic agents or foods fighting against many diseases in the aged people such as cardiovascular diseases and cancers. In this study, we investigated sizes and weights of tumors derived from mice injected subcutaneously with tumorigenic cells to see if antitumor activity would be found in mice dieted with the chlarella complex. After BALB/c mice were dieted with $5\%$ organic cultured chlorella complex diet throughout for 19weeks, the fibrosarcoma was induced by subcutaneous injection of tumorigenic cells at the 3 weeks before sacrifice. The average weight of tumors in the diet group were significantly reduced to $60\%\;(P=0.012)$ of the one in control group, indicating that diet with the chlarella complex may have anticancer activity in mice. When the mice were dieted with $5\%$ organic cultured chlorella complex for 4 weeks before injecting the tumorigenic cells in order to see tumor-preventive effect of the diet, the potential preventive activity of the diet against cancer was implicated by the observation that the tumors were greatly reduced in the diet group to $37\%$ (P=0.l44) of the control group. Especially, when the $5\%$ diet were applied to mice after injecting with the tumorigenic cells, the tumors derived from the $5\%$ diet group were also decreased to $95\%$ (P=0.002) of those in the control group, suggesting that the diet with the organic cultured chlorella complex may also have therapeutic effect against tumor formation. As results, it was shown that the chlorella complex tested in this study had preventive and therapeutic effects on fighting against tumorigenesis. Therefore, the identification and further mechanistic study of the components which may be associated with antitumor activity from diet of the chlorella complex in the future will contribute to the development of anticancer probiotic foods, alternative therapeutic treatment against cancer, and a new anticancer drug.

  • PDF

신속 진단 킷트를 활용한 한우 송아지의 설사증 원인체 검사 (Use of rapid diagnostic kit for the diagnosis of Korean native calf diarrhea)

  • 최창용;정영훈;도윤정;조아라;김성범;강희성;류재규;박진호
    • 한국동물위생학회지
    • /
    • 제40권1호
    • /
    • pp.61-66
    • /
    • 2017
  • Calf diarrhea is a disease experienced by almost all of calves after birth and is one of the representative causes of damage to farmers due to mass mortality and of economic losses to them by inhibiting normal growth. In this study, we conducted quick detection of etiologic agents of diarrhea by using a rapid diagnostic kit to multiply diagnose antigens of five etiologic agents of calf diarrhea (rotavirus, coronavirus, Escherichia coli, Cryptosporidium, Giardia) in Hanwoo (Korean native cattle) calves. When the positive antigen proportion of the calf diarrheal feces for each farm was analyzed, rotavirus, coronavirus, Escherichia coli, Cryptosporidium, and Giardia showed antigen positive rates of 0~67%, 0~20%, 0~60%, 0~20%, and 0~67%, respectively. With regard to the antigen positive rate by age in days after birth, 1-week-old calves showed the antigen positive rate of 20% in rotavirus and 20% in Giardia, and 2-week-old calves showed that of 50% in rotavirus. In addition, 4-week-old calves showed the antigen positive rate of 10% in rotavirus, 10% in coronavirus, 10% in Escherichia coli, and 30% in Giardia, and 8-week-old calves showed the antigen positive rate of 17% in coronavirus, 50% in Escherichia coli, 17% in Cryptosporidium, and 33% in Giardia. Based on the results of this study, the etiologic agents of diarrhea in Hanwoo calves for each farm are widely distributed. Although younger than 2-week-old calves were strongly positive for rotavirus, older than 4-week-old calves were highly positive for Giardia and Escherichia coli. In conclusion, we considered that a rapid diagnostic kit is an effective method for quick detection of etiologic agents and would be helpful for cattle farmers and veterinarians to select appropriate therapeutic method.

몬테칼로 기법을 이용한 방사선 선량증가 물질에 따른 선량증가 효과 평가 (A Monte Carlo Study of Dose Enhancement according to the Enhancement Agents)

  • 김정훈;김창수;황철환
    • 대한방사선기술학회지:방사선기술과학
    • /
    • 제40권1호
    • /
    • pp.93-99
    • /
    • 2017
  • Monte Carlo 시뮬레이션을 이용하여 MV X, ${\gamma}$선에서의 선량증가 효과를 평가하였다. MCNPX code를 이용하여 ICRU 평판형(Slab) 모의피폭체를 전산모사하였으며, 입사 광자의 에너지, 선량증가 물질의 종류 및 농도에 따른 영향을 분석하였다. 선량증가 물질은 금(aurum), 가돌리늄(gadolinium), 요오드(iodine), 산화철(iron oxide)에 대해 비교 평가하였으며, 입사에너지는 선형가속기에서 발생된 4, 6, 10, 15 MV X선의 스펙트럼과 Co 60의 ${\gamma}$선원을 사용하였다. 모의피폭체 내에 7, 18, 30 mg/g 농도의 물질을 삽입하였으며, 선량증가 효과의 정량적 평가를 위해 선량증가비를 산출하였다. X선의 입사에너지가 낮을수록, 선량증가 물질의 농도가 높을수록 높은 선량증가비를 나타내었으며, 최대 선량증가비는 금 1.079, 가돌리늄 1.062, 요오드 1.049, 산화철 1.035를 보여 금, 가돌리늄, 요오드, 산화철 입자 순으로 높은 선량증가 효과를 보였다. 이러한 결과는 In-vivo, vitro 연구의 기초자료로 활용할 수 있을 것으로 사료된다.

태반유래 줄기세포와 골수유래 줄기세포에서의 마이크로RNA 발현비교 (Comparison of MicroRNA Expression in Placenta-derived Mesenchymal Stem Cells and Bone Marrow-derived Stem Cells)

  • 김수환
    • 생명과학회지
    • /
    • 제24권11호
    • /
    • pp.1238-1243
    • /
    • 2014
  • 중간엽줄기세포(mesenchymal stem cell, MSC)은 세포치료로 각광받아 널리 사용되고 있다. 이들은 줄기세포의 분화성을 이용하여 많은 만성질환에 연관되어 치료제로 사용되고 있다. 줄기세포는 다른 화학적 치료법에 비해 많은 장점을 가지고 있다. 왜냐하면 줄기세포치료는 자기자신, 혹은 동종의 세포를 이용한 치료이기 때문에 화학 치료에 비해 부작용이나 치료의 위험성이 덜하다. 그리고 마이크로RNA또한 최근 기 존재와 기능이 밝혀져서 연구되고 있는데 특히 항암, 세포생장촉진 등의 기능을 이용해 항암, 만성질환 치료에 접목되어 치료제로의 역할이 기대된다. 마이크로RNA는 대부분의 대사과정이나 항상성조절에 관여되어있다. 따라서 마이크로RNA가 저 발현 혹은 과 발현하게 되면 만성질환으로 이어지게 된다. 하지만 줄기세포와 마이크로RNA의 상호간 보조효과는 잘 연구되어 있지 않다. 따라서 이들 간의 상관관계를 확인하기 위하여 태반유래 줄기세포(PDSC)와 골수줄기세포(BM-MSC), 대조군으로 섬유아세포(Fibroblast, WI-38)을 사용하여 이들이 발현하는 마이크로RNA 발현을 확인해 보았다. 각각의 MSC 세포주에 대하여 특정 마이크로RNA의 발현량을 확인해 보았다. 결과 PDSC의 경우엔 마이크로RNA-34a의 발현이 높았고 BM-MSC의 경우에는 마이크로RNA-27a, 33a, 33b, 211의 발현이 높은 것을 확인할 수 있었다. 따라서 우리는 각각의 MSC세포주와 그들이 발현하는 기능성 마이크로RNA을 연관지어 효과적인 세포치료에 활용될 수 있을 것을 기대한다.

Therapeutic Effect of Injection-Acupuncture with Bee-Venom (Apitoxin) in Cases of Canine Otitis Externa

  • Kim, Sang-Hun;Jun, Hyung-Kyou;Kim, Suk;You, Myung-Jo;Jun, Moo-Hyung;Kim, Duck-Hwan
    • 한국임상수의학회지
    • /
    • 제25권3호
    • /
    • pp.159-164
    • /
    • 2008
  • This study was carried out to determine the therapeutic effect of injection-acupuncture (AP) with bee-venom (apitoxin) in cases of canine otitis externa (COE). Fifteen dogs with naturally-acquired otitis externa were used in this study. The dogs were divided into the following antibiotics group (control group), apitoxin group (experimental group A) and apitoxin combined with antibiotics group (experimental group B). All groups were treated by ear cleaning with normal saline once on day 1. The control group was treated with susceptible antibiotics, and experimental group A was given injection-AP with apitoxin $(100{\mu}g/head)$ at TH17 (Yi Feng), SI19 (Ting Gong), GB03 (Shang Guan) and TH03 (Zhong Zhu) bilaterally. Experimental group B was treated with susceptible antibiotics and injection-AP with apitoxin at the same acupoints as experimental group A. All the groups were treated 3 times/week for 2 weeks. The identity of the causative agents, the changes in the clinical signs, otoscopic findings, bacterial count in the auricular discharges, and total WBC counts and neutrophil/lymphocyte (N/L) ratio in the peripheral blood were investigated in all groups. In bacterial isolation, Staphylococcus spp. combined with Streptococcus spp. was detected higher than other agents. The bacterial cell count in experimental group A was significantly decreased at 2 weeks (p<0.01), and those in experimental group B was significantly decreased at 1 week (p<0.01) and 2 weeks (p<0.01) compared by those of control group, respectively. The changes of clinical score in experimental group B were significantly decreased at 2 weeks (p<0.01) compared by those of control group, but, those of experimental group A was similar to those of control group. The changes of total WBC counts and neutrophil/lymphocyte (N/L) ratio were no significant difference found. In conclusion, injection-AP with apitoxin is an effective treatment for COE and might be an alternative method for treating COE.

Probiotics의 병원성미생물에 대한 길항적 억제효과 (Antagonistic inhibitory effects of probiotics against pathogenic microorganisms in vitro)

  • 육영삼;이영기;김가연
    • 한국산학기술학회논문지
    • /
    • 제20권12호
    • /
    • pp.110-116
    • /
    • 2019
  • Probiotics와 다양한 병원성 미생물간의 혼합배양에서의 길항적 억제효과를 조사하기 위해 2016년 1월부터 12월까지 국내 김치로부터 다양한 probiotics 균주를 분리하여 16S rRNA sequencing을 통한 계통학적 분석을 통해 140주의 프로바이오틱스를 동정하였다. 이중 항균력이 우수한 probiotics 4종(Enterococcus faecalis, Lactobacillus plantarum, Lactobacillus rhamnosus, and Lactobacillus reuteri )과 병원성 미생물 6종 (Candida albicans, Salmonella Enteritidis, E. coli O157:H7, Shigella flexneri, Staphylococcus aureus, and Pseudomonas aeruginosa)간의 혼합배양에서의 길항적 억제시험에서 probiotics 균주들은 대부분 배양 후에 균수가 정상적으로 크게 증가했지만 C. albicans를 포함하여 대부분의 병원성미생물들은 S. Enteritidis 를 제외하고 거의 완전하게 성장이 억제되었다. 이러한 in vitro 에서의 길항적 억제효과는 생성된 젖산과 유기산등의 낮은 pH에 의한 효과인 것으로 생각된다. 이상의 결과로 한국 김치에서 분리된 probiotics 균주 4종은 여성질염, 대장 및 피부관리 관련 치료제로써의 개발 가능성이 매우 큰 것으로 생각되며 향후 이러한 치료제는 probiotics 관련 국민건강 및 보건향상에 크게 기여할 것으로 생각된다.

제 2형 당뇨병 환자에서 사상체질에 따른 경구 혈당강하요법의 치료 반응성 및 사용 패턴 평가 (The Difference of Efficacy for Oral Hypoglysemic Pharmacotherapy Based on Sasang Constitutional Medicine Among Type II Diabetes Mellitus Patients in Korea)

  • 김지연;이명구;김정태;임성실
    • 약학회지
    • /
    • 제58권1호
    • /
    • pp.71-79
    • /
    • 2014
  • Although Korean patients with type 2 diabetes mellitus (T2DM) are generally treated by western medicine, many of them strongly believe in the traditional oriental Sasang constitutional classification and depend on it for food, health supplements, and oriental medicines decision making. Sasang constitutional classification is a part of traditional Korean medicine that divides people into four constitutional types (Tae-Yang: TY, Tae-Eum: TE, So-Yang: SY, and So-Eum: SE), which differ in inherited characteristics such as appearance, personality traits, susceptibility to diseases, and drug responses. It is recommended for T2DM patients to control their blood glucose very well from early stages with drugs and diet. However, many T2DM patients respond differently to their drugs, even though they receive the same medicine. Therefore, the present study investigated whether Sasang constitutional type can explain the therapeutic differences between oral hypoglycemic agents (OHAs) therapy (mono, dual and triple drug therapy). Patients of 618 with T2DM diagnosis and Sasang constitutional type known who received both western and oriental medicine treatment in a hospital between April 2006 and April 2013 retrospectively studied. HbA1c (%) and blood glucose (mg/dl) levels before OHAs therapy and 3 month after were collected for metformin (MET) or sulfonylurea (SU) monotherapy, MET+SU dual therapy, MET+except SU (where was either alpha-glucosidase inhibitor, dipeptidyl peptidase-4 inhibitor, meglitinide or thiazolidinedione) dual therapy, and triple therapy, according to Sasang constitutional type. For statistical analysis, ANOVA was used and paired t-test by SPSS 19.0 where P values less than 0.05 were considered statistically significant. Pattern was similar levels of HbA1c and blood glucose and which was decreased in order of mono, MET+SU dual, MET+except SU dual and triple therapy. In all patients comparison, for the So-yang (SY) constitutional type, either monotherapy was less effective; for Te-eum (TE) type, MET+SU dual therapy was less effective while MET+except SU dual therapy was more effective and the triple therapy was less effective; and for So-eum (SE) type, the triple therapy was more effective. For the management of TE type it is recommended to use drugs except SU when dual therapy is needed, restrict triple therapy and consider dual and insulin therapy; for SY type it is recommended to follow current guidelines; and for SE type it is advisable to skip dual therapy and start the triple therapy early. Finally, the therapeutic response to OHAs is different among Korean T2DM patients with different Sasang constitutional types. Taken together, the choice of effective OHAs therapy for each type is necessary in order to minimize the poor control of blood glucose level, the risk of complications, and the costs from a failure of therapy.